Treatment of ventilator-associated pneumonia due to carbapenem-resistant Gram-negative bacteria with novel agents: a contemporary, multidisciplinary ESGCIP perspective

References

• Asehnoune K, Seguin P, Allary J, et al. Hydrocortisone and fludrocortisone for prevention of hospital-acquired pneumonia in patients with severe traumatic brain injury (Corti-TC): a double-blind, multicentre phase 3, randomised placebo-controlled trial. Lancet Respir Med. 2014 Sep;2(9):706–716. DOI:https://doi.org/10.1016/S2213-2600(14)70144-4.
   PubMed Web of Science ®Google Scholar
• Cook DJ, Walter SD, Cook RJ, et al. Incidence of and risk factors for ventilator-associated pneumonia in critically ill patients. Ann Intern Med. 1998 Sep 15;129(6):433–440.
   PubMed Web of Science ®Google Scholar
• Rello J, Ollendorf DA, Oster G, et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest. 2002 Dec;122(6):2115–2121. DOI:https://doi.org/10.1378/chest.122.6.2115.
   PubMed Web of Science ®Google Scholar
• Torres A, Cilloniz C, Niederman MS, et al. Pneumonia. Nat Rev Dis Primers. 2021 Apr 8;7(1):25. DOI:https://doi.org/10.1038/s41572-021-00259-0.
   PubMed Web of Science ®Google Scholar
• Torres A, Niederman MS, Chastre J, et al. International ERS/ESICM/ESCMID/ALAT guidelines for the management of hospital-acquired pneumonia and ventilator-associated pneumonia: guidelines for the management of hospital-acquired pneumonia (HAP)/ventilator-associated pneumonia (VAP) of the European Respiratory Society (ERS), European Society of Intensive Care Medicine (ESICM), European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and Asociacion Latinoamericana del Torax (ALAT). Eur Respir J. 2017 Sep;50(3):1700582 .
   Google Scholar
• Barbier F, Andremont A, Wolff M, et al. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med. 2013 May;19(3):216–228. DOI:https://doi.org/10.1097/MCP.0b013e32835f27be.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Righi E, Vena A, et al. Risk stratification and treatment of ICU-acquired pneumonia caused by multidrug- resistant/extensively drug-resistant/pandrug-resistant bacteria. Curr Opin Crit Care. 2018 Oct;24(5):385–393. DOI:https://doi.org/10.1097/MCC.0000000000000534.
   PubMed Web of Science ®Google Scholar
• Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated Pneumonia: 2016 clinical practice guidelines by the infectious diseases society of America and the American thoracic society. Clin Infect Dis. 2016 Sep 1;63(5):e61–e111. DOI:https://doi.org/10.1093/cid/ciw353.
   PubMed Web of Science ®Google Scholar
• Talbot GH, Das A, Cush S, et al. Evidence-Based Study Design for Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia. J Infect Dis. 2019 Apr 19;219(10):1536–1544.
   PubMed Web of Science ®Google Scholar
• Papazian L, Klompas M, Luyt CE. Ventilator-associated pneumonia in adults: a narrative review. Intensive Care Med. 2020 May;46(5):888–906.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Mikulska M, Viscoli C. Recent advances in the pharmacological management of infections due to multidrug-resistant Gram-negative bacteria. Expert Rev Clin Pharmacol. 2018 Dec;11(12):1219–1236.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Giamarellou H, et al. Management of KPC-producing Klebsiella pneumoniae infections. Clin Microbiol Infect. 2018 Feb;24(2):133–144. DOI:https://doi.org/10.1016/j.cmi.2017.08.030.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Antoniadou A, Giamarellou H. Combination therapy for extensively-drug resistant gram-negative bacteria. Expert Rev Anti Infect Ther. 2017 Dec;15(12):1123–1140.
   PubMed Web of Science ®Google Scholar
• Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID. Infectious Diseases Society of America (IDSA), International Society for Anti-infective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy. 2019;Jan 391:10–39.
   Google Scholar
• Niederman MS, Alder J, Bassetti M, et al. Inhaled amikacin adjunctive to intravenous standard-of-care antibiotics in mechanically ventilated patients with Gram-negative pneumonia (INHALE): a double-blind, randomised, placebo-controlled, phase 3, superiority trial. Lancet Infect Dis. 2020 Mar;20(3):330–340. DOI:https://doi.org/10.1016/S1473-3099(19)30574-2.
   PubMed Web of Science ®Google Scholar
• Rouby JJ, Sole-Lleonart C, Rello J, et al. Ventilator-associated pneumonia caused by multidrug-resistant Gram-negative bacteria: understanding nebulization of aminoglycosides and colistin. Intensive Care Med. 2020 Apr;46(4):766–770. DOI:https://doi.org/10.1007/s00134-019-05890-w.
   PubMed Web of Science ®Google Scholar
• Giacobbe DR, Karaiskos I, Bassetti M. How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients? Expert Opin Pharmacother. 2021 Aug;17:1–4.
   Google Scholar
• Zhu Y, Monsel A, Roberts JA, et al. Nebulized Colistin in Ventilator-Associated Pneumonia and Tracheobronchitis: historical Background, Pharmacokinetics and Perspectives. Microorganisms. 2021 May 27;9(6):1154.
   PubMed Web of Science ®Google Scholar
• Karaiskos I, Galani I, Souli M, et al. Novel beta-lactam-beta-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opin Drug Metab Toxicol. 2019 Feb;15(2):133–149. DOI:https://doi.org/10.1080/17425255.2019.1563071.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Russo C, Vena A, et al. New antibiotics for the treatment of nonfermenting Gram-negative bacteria. Curr Opin Infect Dis. 2021 Jul 22;34(6):701–709.
   PubMed Web of Science ®Google Scholar
• Candel FJ, Santerre Henriksen A, Longshaw C, et al. In vitro activity of the novel siderophore cephalosporin, cefiderocol, in Gram-negative pathogens in Europe by site of infection. Clin Microbiol Infect. 2021 Jul 21;28(3):447.e1–447.e6.
   PubMedGoogle Scholar
• Giani T, Arena F, Pollini S, et al. Italian nationwide survey on Pseudomonas aeruginosa from invasive infections: activity of ceftolozane/tazobactam and comparators, and molecular epidemiology of carbapenemase producers. J Antimicrob Chemother. 2018 Mar 1;73(3):664–671.
   PubMed Web of Science ®Google Scholar
• Sader HS, Castanheira M, Shortridge D, et al. Antimicrobial activity of ceftazidime-avibactam tested against multidrug-resistant enterobacteriaceae and pseudomonas aeruginosa isolates from U.S. medical centers, 2013 to 2016. Antimicrob Agents Chemother. 2017 Nov;61(11). doi:https://doi.org/10.1128/AAC.01045-17.
   Web of Science ®Google Scholar
• Shortridge D, Carvalhaes C, Deshpande L, et al. Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19). J Antimicrob Chemother. 2021 Sep 15;76(10):2600–2605.
   PubMed Web of Science ®Google Scholar
• Walkty A, Karlowsky JA, Baxter MR, et al. In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019. Diagn Microbiol Infect Dis. 2021 Sep;101(1):115418. DOI:https://doi.org/10.1016/j.diagmicrobio.2021.115418.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Poulakou G, Timsit JF. Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU. Intensive Care Med. 2016 Jun;42(6):955–958.
   PubMed Web of Science ®Google Scholar
• Timsit JF, Bassetti M, Cremer O, et al. Rationalizing antimicrobial therapy in the ICU: a narrative review. Intensive Care Med. 2019 Feb;45(2):172–189. DOI:https://doi.org/10.1007/s00134-019-05520-5.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Portunato F, Roberts JA. Prolonged infusion of beta-lactam antibiotics for Gram-negative infections: rationale and evidence base. Curr Opin Infect Dis. 2020 Dec;33(6):501–510.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Bassetti M, Francois B, et al. The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship. Intensive Care Med. 2017 Sep;43(9):1187–1197. DOI:https://doi.org/10.1007/s00134-017-4682-7.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Giacobbe DR, Peghin M, et al. A look at clinical trial design for new antimicrobials for the adult population. Expert Rev Clin Pharmacol. 2019 Nov;12(11):1037–1046. DOI:https://doi.org/10.1080/17512433.2019.1680283.
   PubMed Web of Science ®Google Scholar
• Boucher HW, Ambrose PG, Chambers HF, et al. White Paper: developing antimicrobial drugs for resistant pathogens, narrow-spectrum indications, and unmet needs. J Infect Dis. 2017 Jul 15;216(2):228–236.
   PubMed Web of Science ®Google Scholar
• de Kraker Mea, Sommer H, de Velde F, et al. Optimizing the design and analysis of clinical trials for antibacterials against multidrug-resistant organisms: a white paper from COMBACTE’s STAT-Net. Clin Infect Dis. 2018 Nov 28;67(12):1922–1931.
   PubMed Web of Science ®Google Scholar
• Evans SR, Rubin D, Follmann D, et al. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). Clin Infect Dis. 2015 Sep 1;61(5):800–806.
   PubMed Web of Science ®Google Scholar
• Huque MF, Valappil T, Soon GG. Hierarchical nested trial design (HNTD) for demonstrating treatment efficacy of new antibacterial drugs in patient populations with emerging bacterial resistance. Stat Med. 2014 Nov 10;33(25):4321–4336.
   PubMed Web of Science ®Google Scholar
• Woodcock J, LaVange LM. Master protocols to study multiple therapies, multiple diseases, or both. N Engl J Med. 2017 Jul 6;377(1):62–70.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis. 2021 Feb;21(2):226–240. DOI:https://doi.org/10.1016/S1473-3099(20)30796-9.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Novacek M, Kivistik U, et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2019 Dec;19(12):1299–1311. DOI:https://doi.org/10.1016/S1473-3099(19)30403-7.
   PubMed Web of Science ®Google Scholar
• Titov I, Wunderink RG, Roquilly A, et al. A Randomized, double-blind, multicenter trial comparing efficacy and safety of imipenem/cilastatin/relebactam versus piperacillin/tazobactam in adults with hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis. 2021 Dec;73(11):e4539–e4548
   PubMed Web of Science ®Google Scholar
• Torres A, Zhong N, Pachl J, et al. Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial. Lancet Infect Dis. 2018 Mar;18(3):285–295. DOI:https://doi.org/10.1016/S1473-3099(17)30747-8.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Giamarellos-Bourboulis EJ, Rahav G, et al. Effect and Safety of meropenem-vaborbactam versus best-available therapy in patients with carbapenem-resistant enterobacteriaceae infections: the TANGO II randomized clinical trial. Infect Dis Ther. 2018 Dec;7(4):439–455. DOI:https://doi.org/10.1007/s40121-018-0214-1.
   PubMed Web of Science ®Google Scholar
• Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2021 Feb;21(2):213–225. DOI:https://doi.org/10.1016/S1473-3099(20)30731-3.
   PubMed Web of Science ®Google Scholar
• Weiss E, Zahar JR, Alder J, et al. Elaboration of consensus clinical endpoints to evaluate antimicrobial treatment efficacy in future hospital-acquired/ventilator-associated bacterial pneumonia clinical trials. Clin Infect Dis. 2019 Nov 13;69(11):1912–1918.
   PubMed Web of Science ®Google Scholar
• Johnson MG, Bruno C, Castanheira M, et al. Evaluating the emergence of nonsusceptibility among Pseudomonas aeruginosa respiratory isolates from a phase-3 clinical trial for treatment of nosocomial pneumonia (ASPECT-NP). Int J Antimicrob Agents. 2021 Mar;57(3):106278. DOI:https://doi.org/10.1016/j.ijantimicag.2021.106278.
   PubMed Web of Science ®Google Scholar
• Castanheira M, Johnson MG, Yu B, et al. Molecular characterization of baseline enterobacterales and pseudomonas aeruginosa isolates from a phase 3 nosocomial pneumonia (ASPECT-NP) clinical trial. Antimicrob Agents Chemother. 2021 Feb 17;65(3). DOI:https://doi.org/10.1128/AAC.02461-20.
   Google Scholar
• Cisneros JM, Rosso-Fernandez CM, Roca-Oporto C, et al. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (magic bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit Care. 2019 Nov 28;23(1):383.
   PubMed Web of Science ®Google Scholar
• Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis. 2013 Aug;57(3):349–358. DOI:https://doi.org/10.1093/cid/cit253.
   PubMed Web of Science ®Google Scholar
• Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis. 2018 Apr;18(4):391–400. DOI:https://doi.org/10.1016/S1473-3099(18)30099-9.
   PubMed Web of Science ®Google Scholar
• Kadri SS, Adjemian J, Lai YL, et al. Difficult-to-treat resistance in gram-negative bacteremia at 173 US hospitals: retrospective cohort analysis of prevalence, predictors, and outcome of resistance to all first-line agents. Clin Infect Dis. 2018 Nov 28;67(12):1803–1814.
   PubMed Web of Science ®Google Scholar
• Betrosian AP, Frantzeskaki F, Xanthaki A, et al. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis. 2007;39(1):38–43. DOI:https://doi.org/10.1080/00365540600951184.
   PubMed Web of Science ®Google Scholar
• Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect. 2013 Jun;141(6):1214–1222. DOI:https://doi.org/10.1017/S095026881200194X.
   PubMed Web of Science ®Google Scholar
• Khalili H, Shojaei L, Mohammadi M, et al. Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia. J Comp Eff Res. 2018 Sep;7(9):901–911. DOI:https://doi.org/10.2217/cer-2018-0037.
   PubMed Web of Science ®Google Scholar
• Makris D, Petinaki E, Tsolaki V, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med. 2018 Feb;22(2):67–77. DOI:https://doi.org/10.4103/ijccm.IJCCM_302_17.
   PubMed Web of Science ®Google Scholar
• Mosaed R, Haghighi M, Kouchak M, et al. Interim Study: comparison of safety and efficacy of levofloxacin plus colistin regimen with levofloxacin plus high dose ampicillin/sulbactam infusion in treatment of ventilator-associated pneumonia due to multi drug resistant Acinetobacter. Iran J Pharm Res. 2018;17(Suppl2):206–213.
   PubMedGoogle Scholar
• Park HJ, Cho JH, Kim HJ, et al. Colistin monotherapy versus colistin/rifampicin combination therapy in pneumonia caused by colistin-resistant Acinetobacter baumannii: a randomised controlled trial. J Glob Antimicrob Resist. 2019 Jun;17:66–71.
   PubMed Web of Science ®Google Scholar
• Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014 Sep;58(9):5598–5601.
   PubMed Web of Science ®Google Scholar
• Tulli G, Messori A, Trippoli S, et al. Non-inferiority of colistin compared with standard care for the treatment of ventilator-associated pneumonia. Int J Antimicrob Agents. 2017 May;49(5):638–641. DOI:https://doi.org/10.1016/j.ijantimicag.2017.01.013.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ortiz-Leyba C, Jimenez-Jimenez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis. 2003 May 1;36(9):1111–1118.
   PubMed Web of Science ®Google Scholar
• Florescu DF, Qiu F, McCartan MA, et al. What is the efficacy and safety of colistin for the treatment of ventilator-associated pneumonia? A systematic review and meta-regression. Clin Infect Dis. 2012 Mar 1;54(5):670–680.
   PubMed Web of Science ®Google Scholar
• Kallel H, Hergafi L, Bahloul M, et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med. 2007 Jul;33(7):1162–1167. DOI:https://doi.org/10.1007/s00134-007-0675-2.
   PubMed Web of Science ®Google Scholar
• Rigatto MH, Ribeiro VB, Konzen D, et al. Comparison of polymyxin B with other antimicrobials in the treatment of ventilator-associated pneumonia and tracheobronchitis caused by Pseudomonas aeruginosa or Acinetobacter baumannii. Infection. 2013 Apr;41(2):321–328. DOI:https://doi.org/10.1007/s15010-012-0349-z.
   PubMed Web of Science ®Google Scholar
• Nation RL, Forrest A. Clinical Pharmacokinetics, Pharmacodynamics and Toxicodynamics of Polymyxins: implications for Therapeutic Use. Adv Exp Med Biol. 2019;1145:219–249.
   PubMed Web of Science ®Google Scholar
• Pogue JM, Kaye KS, Veve MP, et al. Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020 Jul 11;71(2):304–310.
   PubMed Web of Science ®Google Scholar
• Vena A, Giacobbe DR, Mussini C, et al. Clinical efficacy of ceftolozane-tazobactam versus other active agents for the treatment of Bacteremia and Nosocomial Pneumonia due to Drug-Resistant Pseudomonas aeruginosa. Clin Infect Dis. 2020 Oct 23;71(7):1799–1801.
   PubMed Web of Science ®Google Scholar
• Almangour TA, Aljabri A, Almusawa M, et al. Ceftolozane-tazobactam versus colistin for the treatment of infections due to drug-resistant Pseudomonas aeruginosa. A multicenter cohort study. J Glob Antimicrob Resist. 2022;28:288–294.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae Carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019 Jan 18;68(3):355–364.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-Avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae Bacteremia. Antimicrob Agents Chemother. 2017 Aug;61(8). doi:https://doi.org/10.1128/AAC.00883-17.
   Web of Science ®Google Scholar
• van Duin D, Lok JJ, Earley M, et al. Colistin Versus Ceftazidime-Avibactam in the Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect Dis. 2018 Jan 6;66(2):163–171.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing k. pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021 Nov 2;73(9):1664–1676.
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, et al. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant enterobacteriaceae infections. Antimicrob Agents Chemother. 2018 May;62(5). doi:https://doi.org/10.1128/AAC.02497-17.
   Web of Science ®Google Scholar
• Vena A, Giacobbe DR, Castaldo N, et al. clinical experience with ceftazidime-avibactam for the treatment of infections due to multidrug-resistant gram-negative bacteria other than carbapenem-resistant enterobacterales. Antibiotics (Basel). 2020 Feb 9;9(2):71.
   Web of Science ®Google Scholar
• Liu X, Chu Y, Yue H, et al. Risk factors for and clinical outcomes of ceftazidime-avibactam-resistant carbapenem-resistant Klebsiella pneumoniae nosocomial infections: a single-center retrospective study. Infection. 2022. DOI:https://doi.org/10.1007/s15010-022-01781-3.
   Google Scholar
• Corbella L, Boán J, San-Juan R, et al. Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa. Int J Antimicrob Agents. 2022;59(2):106517.
   PubMedGoogle Scholar
• Balandín B, Ballesteros D, Pintado V, et al. Multicentre study of ceftazidime/avibactam for Gram-negative bacteria infections in critically ill patients. Int J Antimicrob Agents. 2022;59(3):106536.
   PubMedGoogle Scholar
• Shi Y, Hu J, Liu P, et al. Ceftazidime-Avibactam-based versus tigecycline-based regimen for the Treatment of Carbapenem-Resistant Klebsiella pneumoniae-Induced Pneumonia in Critically Ill Patients. Infect Dis Ther. 2021;15:1–14.
   Google Scholar
• Almangour TA, Ghonem L, Aljabri A, et al. Ceftazidime-Avibactam versus colistin for the treatment of infections due to carbapenem-resistant enterobacterales: a multicenter cohort study. Infect Drug Resist. 2022 Jan 23;15:211–221. DOI:https://doi.org/10.2147/IDR.S349004.
   PubMed Web of Science ®Google Scholar
• Alosaimy S, Lagnf AM, Morrisette T, et al. Real-world, multicenter experience with meropenem-vaborbactam for gram-negative bacterial infections including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa. Open Forum Infect Dis. 2021 Aug;8(8):ofab371. DOI:https://doi.org/10.1093/ofid/ofab371.
   PubMed Web of Science ®Google Scholar
• Shields RK, McCreary EK, Marini RV, et al. Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis. 2020 Jul 27;71(3):667–671.
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G, Nicastro M, et al. Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients. Clin Infect Dis. 2021 Jun 1;72(11):2021–2024.
   PubMed Web of Science ®Google Scholar
• Gatti M, Bartoletti M, Cojutti PG, et al. A descriptive case series of PK/PD target attainment and microbiological outcome in critically ill patients with documented severe XDR Acinetobacter baumannii BSI and/or VAP treated with cefiderocol. J Glob Antimicrob Resist. 2021 Oct 25;27:294–298. DOI:https://doi.org/10.1016/j.jgar.2021.10.014.
   PubMed Web of Science ®Google Scholar
• Meschiari M, Volpi S, Faltoni M, et al. Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections. JAC Antimicrob Resist. 2021;3(4). DOI:https://doi.org/10.1093/jacamr/dlab188
   Google Scholar
• Rando E, Segala FV, Vargas J, et al. Cefiderocol for Severe Carbapenem-Resistant A. baumannii Pneumonia: towards the Comprehension of Its place in therapy. Antibiotics (Basel). 2021 Dec 21;11(1):3.
   PubMed Web of Science ®Google Scholar
• Falcone M, Tiseo G. Cefiderocol for the treatment of metallo-beta-lactamases producing Gram negative bacilli: lights and shadows from the literature. Clin Infect Dis. 2022. DOI:https://doi.org/10.1093/cid/ciac082
   Google Scholar
• Pascale R, Pasquini Z, Bartoletti M, et al. Cefiderocol treatment for carbapenem-resistant Acinetobacter baumannii infection in the ICU during the COVID-19 pandemic: a multicentre cohort study. JAC Antimicrob Resist. 2021 Nov 17;3(4):dlab174.
   PubMedGoogle Scholar
• Rebold N, Morrisette T, Lagnf AM, et al. Early multicenter experience with imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Open Forum Infect Dis. 2021 Dec 9;8(12):ofab554.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Repetto E, Righi E, et al. Colistin and rifampicin in the treatment of multidrug-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2008 Feb;61(2):417–420. DOI:https://doi.org/10.1093/jac/dkm509.
   PubMed Web of Science ®Google Scholar
• Motaouakkil S, Charra B, Hachimi A, et al. Colistin and rifampicin in the treatment of nosocomial infections from multiresistant Acinetobacter baumannii. J Infect. 2006 Oct;53(4):274–278. DOI:https://doi.org/10.1016/j.jinf.2005.11.019.
   PubMed Web of Science ®Google Scholar
• Saballs M, Pujol M, Tubau F, et al. Rifampicin/imipenem combination in the treatment of carbapenem-resistant Acinetobacter baumannii infections. J Antimicrob Chemother. 2006 Sep;58(3):697–700. DOI:https://doi.org/10.1093/jac/dkl274.
   PubMed Web of Science ®Google Scholar
• FDA Drug Safety Communication. FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning. [ accessed 14 Nov 2021]. Available from: https://www.fda.gov/drugs/drugsafety/ucm369580.htm.
   Google Scholar
• De Pascale G, Montini L, Pennisi M, et al. High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care. 2014 May 5;18(3):R90.
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Ferrandiz-Millon C. High dose of tigecycline for extremely resistant Gram-negative pneumonia: yes, we can. Crit Care. 2014 Jun 24;18(3):157.
   PubMed Web of Science ®Google Scholar
• Wu X, Zhu Y, Chen Q, et al. Tigecycline Therapy for nosocomial pneumonia due to carbapenem-resistant gram-negative bacteria in critically ill patients who received inappropriate initial antibiotic treatment: a retrospective case study. Biomed Res Int. 2016;2016:8395268.
   PubMed Web of Science ®Google Scholar
• Bai XR, Jiang DC, Yan SY. High-Dose tigecycline in elderly patients with pneumonia due to multidrug-resistant acinetobacter baumannii in intensive care unit. Infect Drug Resist. 2020;13:1447–1454.
   PubMed Web of Science ®Google Scholar
• Chen Z, Shi X. Adverse events of high-dose tigecycline in the treatment of ventilator-associated pneumonia due to multidrug-resistant pathogens. Medicine (Baltimore). 2018 Sep;97(38):e12467.
   PubMed Web of Science ®Google Scholar
• He H, Zheng Y, Sun B, et al. Tigecycline combination for ventilator-associated pneumonia caused by extensive drug-resistant Acinetobacter baumannii. J Thorac Dis. 2016 Oct;8(10):2784–2792. DOI:https://doi.org/10.21037/jtd.2016.10.29.
   PubMed Web of Science ®Google Scholar
• Xia G, Jiang R. Clinical study on the safety and efficacy of high-dose tigecycline in the elderly patients with multidrug-resistant bacterial infections: a retrospective analysis. Medicine (Baltimore). 2020 Mar;99(10):e19466.
   PubMed Web of Science ®Google Scholar
• Zha L, Zhang D, Pan L, et al. Tigecycline in the treatment of ventilator-associated pneumonia due to stenotrophomonas maltophilia: a multicenter retrospective cohort study. Infect Dis Ther. 2021 Dec;10(4):2415–2429. DOI:https://doi.org/10.1007/s40121-021-00516-5.
   PubMed Web of Science ®Google Scholar
• Chen CH, Tu CY, Chen WC, et al. Clinical efficacy of cefoperazone-sulbactam versus piperacillin-tazobactam in the treatment of hospital-acquired Pneumonia and Ventilator-Associated Pneumonia. Infect Drug Resist. 2021;14:2251–2258.
   PubMed Web of Science ®Google Scholar
• Kanchanasuwan S, Kositpantawong N, Singkhamanan K, et al. Outcomes of adjunctive therapy with intravenous cefoperazone-sulbactam for ventilator-associated Pneumonia due to carbapenem-resistant acinetobacter baumannii. Infect Drug Resist. 2021;14:1255–1264.
   PubMed Web of Science ®Google Scholar
• Wood GC, Hanes SD, Boucher BA, et al. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med. 2003 Nov;29(11):2072–2076. DOI:https://doi.org/10.1007/s00134-003-1811-2.
   PubMed Web of Science ®Google Scholar
• Wood GC, Hanes SD, Croce MA, et al. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of acinetobacter ventilator-associated pneumonia. Clin Infect Dis. 2002 Jun 1;34(11):1425–1430.
   PubMed Web of Science ®Google Scholar
• Fragkou PC, Poulakou G, Blizou A, et al. The role of minocycline in the treatment of nosocomial infections caused by multidrug, extensively drug and pandrug resistant acinetobacter baumannii: a systematic review of clinical evidence. Microorganisms. 2019 Jun 1;7(6):159.
   Web of Science ®Google Scholar
• Apisarnthanarak A, Mundy LM. Carbapenem-resistant Pseudomonas aeruginosa pneumonia with intermediate minimum inhibitory concentrations to doripenem: combination therapy with high-dose, 4-h infusion of doripenem plus fosfomycin versus intravenous colistin plus fosfomycin. Int J Antimicrob Agents. 2012 Mar;39(3):271–272.
   PubMed Web of Science ®Google Scholar
• Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010 Feb;16(2):184–186. DOI:https://doi.org/10.1111/j.1469-0691.2009.02921.x.
   PubMed Web of Science ®Google Scholar
• Dinh A, Salomon J, Bru JP, et al. Fosfomycin: efficacy against infections caused by multidrug-resistant bacteria. Scand J Infect Dis. 2012 Mar;44(3):182–189. DOI:https://doi.org/10.3109/00365548.2011.616221.
   PubMed Web of Science ®Google Scholar
• Khawcharoenporn T, Chuncharunee A, Maluangnon C, et al. Active monotherapy and combination therapy for extensively drug-resistant Pseudomonas aeruginosa pneumonia. Int J Antimicrob Agents. 2018 Dec;52(6):828–834. DOI:https://doi.org/10.1016/j.ijantimicag.2018.09.008.
   PubMed Web of Science ®Google Scholar
• Pyrpasopoulou A, Pitsava G, Iosifidis E, et al. Intravenous fosfomycin in patients with liver disease for extensively drug-resistant Gram-negative bacteria. J Infect. 2018 Nov;77(5):448–454. DOI:https://doi.org/10.1016/j.jinf.2018.07.013.
   PubMed Web of Science ®Google Scholar
• Putensen C, Ellger B, Sakka SG, et al. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019 Oct;47(5):827–836. DOI:https://doi.org/10.1007/s15010-019-01323-4.
   PubMed Web of Science ®Google Scholar
• Russo A, Bassetti M, Bellelli V, et al. Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant Acinetobacter baumannii: a prospective, observational study. Infect Dis Ther. 2021 Mar;10(1):187–200. DOI:https://doi.org/10.1007/s40121-020-00357-8.
   PubMed Web of Science ®Google Scholar
• Sole-Lleonart C, Roberts JA, Chastre J, et al. Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. Clin Microbiol Infect. 2016 Apr;22(4):359–364. DOI:https://doi.org/10.1016/j.cmi.2015.12.016.
   PubMed Web of Science ®Google Scholar
• Ehrmann S, Chastre J, Diot P, et al. Nebulized antibiotics in mechanically ventilated patients: a challenge for translational research from technology to clinical care. Ann Intensive Care. 2017 Dec;7(1):78. DOI:https://doi.org/10.1186/s13613-017-0301-6.
   PubMedGoogle Scholar
• Rello J, Sole-Lleonart C, Rouby JJ, et al. Use of nebulized antimicrobials for the treatment of respiratory infections in invasively mechanically ventilated adults: a position paper from the European society of clinical microbiology and infectious diseases. Clin Microbiol Infect. 2017 Sep;23(9):629–639. DOI:https://doi.org/10.1016/j.cmi.2017.04.011.
   PubMed Web of Science ®Google Scholar
• Ferrer M, Sequeira T, Cilloniz C, et al. Ventilator-associated Pneumonia and PaO2/FIO2 diagnostic accuracy: changing the Paradigm? J Clin Med. 2019 Aug 14;8(8):1217.
   Web of Science ®Google Scholar
• Tang R, Luo R, Wu B, et al. Effectiveness and safety of adjunctive inhaled antibiotics for ventilator-associated pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Crit Care. 2021 Oct;65:133–139.
   PubMed Web of Science ®Google Scholar
• Liu C, Zhang YT, Peng ZY, et al. Aerosolized Amikacin as adjunctive therapy of ventilator-associated Pneumonia caused by multidrug-resistant gram-negative bacteria: a single-center randomized controlled trial. Chin Med J (Engl). 2017 May 20;130(10):1196–1201.
   PubMed Web of Science ®Google Scholar
• Nassar Y, Saber-Ayad M, Shash R. Combined microbiological and clinical outcomes of short-term inhaled colistin adjunctive therapy in ventilator-associated pneumonia. The Egyptian Journal of Chest Diseases and Tuberculosis. 2018;67(4):376–383.
   Web of Science ®Google Scholar
• Ammar MA, Abdalla W. Effect of extended infusion of meropenem and nebulized amikacin on Gram-negative multidrug-resistant ventilator-associated pneumonia. Saudi J Anaesth. 2018 Jan-Mar;12(1):89–94.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Ricard JD, Roux D, et al. A Randomized Trial of the Amikacin fosfomycin inhalation system for the adjunctive therapy of Gram-negative ventilator-associated pneumonia: IASIS trial. Chest. 2017 Jun;151(6):1239–1246. DOI:https://doi.org/10.1016/j.chest.2016.11.026.
   PubMed Web of Science ®Google Scholar
• Abdellatif S, Trifi A, Daly F, et al. Efficacy and toxicity of aerosolised colistin in ventilator-associated pneumonia: a prospective, randomised trial. Ann Intensive Care. 2016 Dec;6(1):26. DOI:https://doi.org/10.1186/s13613-016-0127-7.
   PubMed Web of Science ®Google Scholar
• Lu Q, Luo R, Bodin L, et al. Efficacy of high-dose nebulized colistin in ventilator-associated pneumonia caused by multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. Anesthesiology. 2012 Dec;117(6):1335–1347. DOI:https://doi.org/10.1097/ALN.0b013e31827515de.
   PubMed Web of Science ®Google Scholar
• Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis. 1998 Jan;26(1):1–10; quiz 11–2.
   Web of Science ®Google Scholar
• Drusano GL. Antimicrobial pharmacodynamics: critical interactions of bug and drug. Nat Rev Microbiol. 2004 Apr;2(4):289–300.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med. 2020 Jun;46(6):1127–1153. DOI:https://doi.org/10.1007/s00134-020-06050-1.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Lipman J, Mouton JW, et al. Applying pharmacokinetic/pharmacodynamic principles in critically ill patients: optimizing efficacy and reducing resistance development. Semin Respir Crit Care Med. 2015 Feb;36(1):136–153. DOI:https://doi.org/10.1055/s-0034-1398490.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Lipman J, et al. Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions. Lancet Infect Dis. 2014 Jun;14(6):498–509. DOI:https://doi.org/10.1016/S1473-3099(14)70036-2.
   PubMed Web of Science ®Google Scholar
• Drwiega EN, Rodvold KA. Penetration of antibacterial agents into pulmonary epithelial lining fluid: an update. Clin Pharmacokinet. 2021 Oct 15;61(1):17–46.
   PubMed Web of Science ®Google Scholar
• Rodvold KA, George JM, Yoo L. Penetration of anti-infective agents into pulmonary epithelial lining fluid: focus on antibacterial agents. Clin Pharmacokinet. 2011 Oct;50(10):637–664.
   PubMed Web of Science ®Google Scholar
• Kashuba AD, Nafziger AN, Drusano GL, et al. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother. 1999 Mar;43(3):623–629. DOI:https://doi.org/10.1128/AAC.43.3.623.
   PubMed Web of Science ®Google Scholar
• Aitken SL, Altshuler J, Guervil DJ, et al. Cefepime free minimum concentration to minimum inhibitory concentration (fCmin/MIC) ratio predicts clinical failure in patients with Gram-negative bacterial pneumonia. Int J Antimicrob Agents. 2015 May;45(5):541–544. DOI:https://doi.org/10.1016/j.ijantimicag.2014.12.018.
   PubMed Web of Science ®Google Scholar
• Crandon JL, Luyt CE, Aubry A, et al. Pharmacodynamics of carbapenems for the treatment of Pseudomonas aeruginosa ventilator-associated pneumonia: associations with clinical outcome and recurrence. J Antimicrob Chemother. 2016 Sep;71(9):2534–2537. DOI:https://doi.org/10.1093/jac/dkw200.
   PubMed Web of Science ®Google Scholar
• Li C, Du X, Kuti JL, et al. Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother. 2007 May;51(5):1725–1730. DOI:https://doi.org/10.1128/AAC.00294-06.
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Mouton JW. Optimal exposures of ceftazidime predict the probability of microbiological and clinical outcome in the treatment of nosocomial pneumonia. J Antimicrob Chemother. 2013 Apr;68(4):900–906.
   PubMed Web of Science ®Google Scholar
• Muller AE, Punt N, Mouton JW. Exposure to ceftobiprole is associated with microbiological eradication and clinical cure in patients with nosocomial pneumonia. Antimicrob Agents Chemother. 2014 May;58(5):2512–2519.
   PubMed Web of Science ®Google Scholar
• Drusano GL, Preston SL, Fowler C, et al. Relationship between fluoroquinolone area under the curve: minimum inhibitory concentration ratio and the probability of eradication of the infecting pathogen, in patients with nosocomial pneumonia. J Infect Dis. 2004 May 1;189(9):1590–1597.
   PubMed Web of Science ®Google Scholar
• Forrest A, Nix DE, Ballow CH, et al. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother. 1993 May;37(5):1073–1081. DOI:https://doi.org/10.1128/AAC.37.5.1073.
   PubMed Web of Science ®Google Scholar
• Moise-Broder PA, Forrest A, Birmingham MC, et al. Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet. 2004;43(13):925–942. DOI:https://doi.org/10.2165/00003088-200443130-00005.
   PubMed Web of Science ®Google Scholar
• Zhou L, Gao Y, Cao W, et al. Retrospective analysis of relationships among the dose regimen, trough concentration, efficacy, and safety of teicoplanin in Chinese patients with moderate-severe Gram-positive infections. Infect Drug Resist. 2018;11:29–36.
   PubMed Web of Science ®Google Scholar
• Boisson M, Jacobs M, Gregoire N, et al. Comparison of intrapulmonary and systemic pharmacokinetics of colistin methanesulfonate (CMS) and colistin after aerosol delivery and intravenous administration of CMS in critically ill patients. Antimicrob Agents Chemother. 2014 Dec;58(12):7331–7339. DOI:https://doi.org/10.1128/AAC.03510-14.
   PubMed Web of Science ®Google Scholar
• Markou N, Fousteri M, Markantonis SL, et al. Colistin pharmacokinetics in intensive care unit patients on continuous venovenous haemodiafiltration: an observational study. J Antimicrob Chemother. 2012 Oct;67(10):2459–2462. DOI:https://doi.org/10.1093/jac/dks257.
   PubMed Web of Science ®Google Scholar
• Imberti R, Cusato M, Villani P, et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest. 2010 Dec;138(6):1333–1339. DOI:https://doi.org/10.1378/chest.10-0463.
   PubMed Web of Science ®Google Scholar
• Matzi V, Lindenmann J, Porubsky C, et al. Extracellular concentrations of fosfomycin in lung tissue of septic patients. J Antimicrob Chemother. 2010 May;65(5):995–998. DOI:https://doi.org/10.1093/jac/dkq070.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Rimmele T, et al. Pharmacokinetics and intrapulmonary diffusion of levofloxacin in critically ill patients with severe community-acquired pneumonia. Crit Care Med. 2005 Jan;33(1):104–109. DOI:https://doi.org/10.1097/01.CCM.0000150265.42067.4C.
   PubMed Web of Science ®Google Scholar
• Kuti JL, Nicolau DP. Presence of infection influences the epithelial lining fluid penetration of oral levofloxacin in adult patients. Int J Antimicrob Agents. 2015 May;45(5):512–518.
   PubMed Web of Science ®Google Scholar
• Leone M, Albanese J, Sampol-Manos E, et al. Moxifloxacin penetration in bronchial secretions of mechanically ventilated patients with pneumonia. Antimicrob Agents Chemother. 2004 Feb;48(2):638–640. DOI:https://doi.org/10.1128/AAC.48.2.638-640.2004.
   PubMed Web of Science ®Google Scholar
• Nicolau DP, Sutherland C, Winget D, et al. Bronchopulmonary pharmacokinetic and pharmacodynamic profiles of levofloxacin 750 mg once daily in adults undergoing treatment for acute exacerbation of chronic bronchitis. Pulm Pharmacol Ther. 2012 Feb;25(1):94–98. DOI:https://doi.org/10.1016/j.pupt.2011.12.007.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xie X, Zhou X, et al. Permeability and concentration of levofloxacin in epithelial lining fluid in patients with lower respiratory tract infections. J Clin Pharmacol. 2010 Aug;50(8):922–928. DOI:https://doi.org/10.1177/0091270009355160.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Cannesson M, et al. Steady-state plasma and intrapulmonary concentrations of piperacillin/tazobactam 4 g/0.5 g administered to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004 May;30(5):976–979. DOI:https://doi.org/10.1007/s00134-004-2222-8.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Saux MC, et al. Pharmacokinetics and lung concentrations of ertapenem in patients with ventilator-associated pneumonia. Intensive Care Med. 2006 Dec;32(12):2059–2062. DOI:https://doi.org/10.1007/s00134-006-0401-5.
   PubMed Web of Science ®Google Scholar
• Caro L, Nicolau DP, De Waele JJ, et al. Lung penetration, bronchopulmonary pharmacokinetic/pharmacodynamic profile and safety of 3 g of ceftolozane/tazobactam administered to ventilated, critically ill patients with pneumonia. J Antimicrob Chemother. 2020 Jun 1;75(6):1546–1553.
   PubMed Web of Science ®Google Scholar
• Felton TW, McCalman K, Malagon I, et al. Pulmonary penetration of piperacillin and tazobactam in critically ill patients. Clin Pharmacol Ther. 2014 Oct;96(4):438–448. DOI:https://doi.org/10.1038/clpt.2014.131.
   PubMed Web of Science ®Google Scholar
• Frippiat F, Musuamba FT, Seidel L, et al. Modelled target attainment after meropenem infusion in patients with severe nosocomial pneumonia: the PROMESSE study. J Antimicrob Chemother. 2015 Jan;70(1):207–216. DOI:https://doi.org/10.1093/jac/dku354.
   PubMed Web of Science ®Google Scholar
• Lodise TP, Sorgel F, Melnick D, et al. Penetration of meropenem into epithelial lining fluid of patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2011 Apr;55(4):1606–1610. DOI:https://doi.org/10.1128/AAC.01330-10.
   PubMed Web of Science ®Google Scholar
• Oesterreicher Z, Minichmayr I, Sauermann R, et al. Pharmacokinetics of doripenem in plasma and epithelial lining fluid (ELF): comparison of two dosage regimens. Eur J Clin Pharmacol. 2017 Dec;73(12):1609–1613. DOI:https://doi.org/10.1007/s00228-017-2327-y.
   PubMed Web of Science ®Google Scholar
• Tomaselli F, Maier A, Matzi V, et al. Penetration of meropenem into pneumonic human lung tissue as measured by in vivo microdialysis. Antimicrob Agents Chemother. 2004 Jun;48(6):2228–2232. DOI:https://doi.org/10.1128/AAC.48.6.2228-2232.2004.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Djabarouti S, et al. Reliability of mini-bronchoalveolar lavage for the measurement of epithelial lining fluid concentrations of tobramycin in critically ill patients. Intensive Care Med. 2007 Sep;33(9):1519–1523. DOI:https://doi.org/10.1007/s00134-007-0688-x.
   PubMed Web of Science ®Google Scholar
• Carcas AJ, Garcia-Satue JL, Zapater P, et al. Tobramycin penetration into epithelial lining fluid of patients with pneumonia. Clin Pharmacol Ther. 1999 Mar;65(3):245–250. DOI:https://doi.org/10.1016/S0009-9236(99)70103-7.
   PubMed Web of Science ®Google Scholar
• Panidis D, Markantonis SL, Boutzouka E, et al. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest. 2005 Aug;128(2):545–552. DOI:https://doi.org/10.1378/chest.128.2.545.
   PubMed Web of Science ®Google Scholar
• Chai MG, Cotta MO, Abdul-Aziz MH, et al. What are the current approaches to optimising antimicrobial dosing in the intensive care unit? Pharmaceutics. 2020 Jul 7;12(7):638.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Driver E, Lipman J, et al. New paradigm for rapid achievement of appropriate therapy in special populations: coupling antibiotic dose optimization rapid microbiological methods. Expert Opin Drug Metab Toxicol. 2018 Jul;14(7):693–708. DOI:https://doi.org/10.1080/17425255.2018.1484452.
   PubMed Web of Science ®Google Scholar
• Awad SS, Rodriguez AH, Chuang YC, et al. A phase 3 randomized double-blind comparison of ceftobiprole medocaril versus ceftazidime plus linezolid for the treatment of hospital-acquired pneumonia. Clin Infect Dis. 2014 Jul 1;59(1):51–61.
   PubMed Web of Science ®Google Scholar
• Bhavnani SM, Rubino CM, Hammel JP, et al. Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother. 2012 Feb;56(2):1065–1072. DOI:https://doi.org/10.1128/AAC.01615-10.
   PubMed Web of Science ®Google Scholar
• Kollef MH, Chastre J, Clavel M, et al. A randomized trial of 7-day doripenem versus 10-day imipenem-cilastatin for ventilator-associated pneumonia. Crit Care. 2012 Nov 13;16(6):R218.
   PubMed Web of Science ®Google Scholar
• Benitez-Cano A, Luque S, Sorli L, et al. Intrapulmonary concentrations of meropenem administered by continuous infusion in critically ill patients with nosocomial pneumonia: a randomized pharmacokinetic trial. Crit Care. 2020 Feb 17;24(1):55.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Duflo F, et al. Steady-state plasma and intrapulmonary concentrations of cefepime administered in continuous infusion in critically ill patients with severe nosocomial pneumonia. Crit Care Med. 2003 Aug;31(8):2102–2106. DOI:https://doi.org/10.1097/01.CCM.0000069734.38738.C8.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Rimmele T, et al. Alveolar concentrations of piperacillin/tazobactam administered in continuous infusion to patients with ventilator-associated pneumonia. Crit Care Med. 2008 May;36(5):1500–1506. DOI:https://doi.org/10.1097/CCM.0b013e318170ba21.
   PubMed Web of Science ®Google Scholar
• Boselli E, Breilh D, Rimmele T, et al. Plasma and lung concentrations of ceftazidime administered in continuous infusion to critically ill patients with severe nosocomial pneumonia. Intensive Care Med. 2004 May;30(5):989–991. DOI:https://doi.org/10.1007/s00134-004-2171-2.
   PubMed Web of Science ®Google Scholar
• Cousson J, Floch T, Guillard T, et al. Lung concentrations of ceftazidime administered by continuous versus intermittent infusion in patients with ventilator-associated pneumonia. Antimicrob Agents Chemother. 2015 Apr;59(4):1905–1909.
   PubMed Web of Science ®Google Scholar
• Abdul-Aziz MH, Sulaiman H, Mat-Nor MB, et al. Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis. Intensive Care Med. 2016 Oct;42(10):1535–1545. DOI:https://doi.org/10.1007/s00134-015-4188-0.
   PubMed Web of Science ®Google Scholar
• Chytra I, Stepan M, Benes J, et al. Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial. Crit Care. 2012 Jun 28;16(3):R113.
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. Continuous infusion of beta-lactam antibiotics in severe sepsis: a multicenter double-blind, randomized controlled trial. Clin Infect Dis. 2013 Jan;56(2):236–244. DOI:https://doi.org/10.1093/cid/cis856.
   PubMed Web of Science ®Google Scholar
• Dulhunty JM, Roberts JA, Davis JS, et al. A Multicenter randomized trial of continuous versus intermittent beta-lactam infusion in severe sepsis. Am J Respir Crit Care Med. 2015 Dec 1;192(11):1298–1305.
   PubMed Web of Science ®Google Scholar
• Fawaz S, Barton S, Nabhani-Gebara S. Comparing clinical outcomes of piperacillin-tazobactam administration and dosage strategies in critically ill adult patients: a systematic review and meta-analysis. BMC Infect Dis. 2020 Jun 20;20(1):430.
   PubMed Web of Science ®Google Scholar
• Rhodes NJ, Liu J, O’Donnell JN, et al. Prolonged infusion piperacillin-tazobactam decreases mortality and improves outcomes in severely ill patients: results of a systematic review and meta-analysis. Crit Care Med. 2018 Feb;46(2):236–243. DOI:https://doi.org/10.1097/CCM.0000000000002836.
   PubMed Web of Science ®Google Scholar
• Yu Z, Pang X, Wu X, et al. Clinical outcomes of prolonged infusion (extended infusion or continuous infusion) versus intermittent bolus of meropenem in severe infection: a meta-analysis. PLoS One. 2018 Jul 30;13(7):e0201667.
   PubMed Web of Science ®Google Scholar
• Roberts JA, Abdul-Aziz MH, Davis JS, et al. Continuous versus intermittent β-lactam infusion in severe sepsis. a meta-analysis of individual patient data from randomized trials. Am J Respir Crit Care Med. 2016 Sep 15;194(6):681–691.
   PubMed Web of Science ®Google Scholar
• Cojutti PG, Lazzarotto D, Candoni A, et al. Real-time TDM-based optimization of continuous-infusion meropenem for improving treatment outcome of febrile neutropenia in oncohaematological patients: results from a prospective, monocentric, interventional study. J Antimicrob Chemother. 2020 Oct 1;75(10):3029–3037.
   PubMed Web of Science ®Google Scholar
• Richter DC, Frey O, Rohr A, et al. Therapeutic drug monitoring-guided continuous infusion of piperacillin/tazobactam significantly improves pharmacokinetic target attainment in critically ill patients: a retrospective analysis of four years of clinical experience. Infection. 2019 Dec;47(6):1001–1011. DOI:https://doi.org/10.1007/s15010-019-01352-z.
   PubMed Web of Science ®Google Scholar
• Paul M, Carrara E, Retamar P, et al. European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by ESICM -European Society of intensive care Medicine). Clin Microbiol Infect. 2022 Apr;28(4):521–547.
   PubMed Web of Science ®Google Scholar
• Bassetti M, Falletta A, Cenderello G, et al. Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections. Expert Opin Drug Saf. 2021;21(4):487–498.
   PubMed Web of Science ®Google Scholar